[go: up one dir, main page]

PE20160124A1 - Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr - Google Patents

Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr

Info

Publication number
PE20160124A1
PE20160124A1 PE2016000013A PE2016000013A PE20160124A1 PE 20160124 A1 PE20160124 A1 PE 20160124A1 PE 2016000013 A PE2016000013 A PE 2016000013A PE 2016000013 A PE2016000013 A PE 2016000013A PE 20160124 A1 PE20160124 A1 PE 20160124A1
Authority
PE
Peru
Prior art keywords
dichloropyridin
indazol
vinyl
ethanol
compound
Prior art date
Application number
PE2016000013A
Other languages
English (en)
Inventor
Daohong Chen
Genshi Zhao
Hong-Yu Li
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20160124A1 publication Critical patent/PE20160124A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona compuestos, caracterizado porque es (E)-2-4(4-(2(5-(1-(3,5-dicloropiridin-4-il) etoxi)-1H-indazol-3-il) vinil)-1H-pirazol-1-il) etanol, o el compuesto (I), o una sal del mismo farmaceuticamente aceptable, util en el tratamiento de cancer
PE2016000013A 2009-05-07 2010-05-04 Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr PE20160124A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17629009P 2009-05-07 2009-05-07
US30141610P 2010-02-04 2010-02-04

Publications (1)

Publication Number Publication Date
PE20160124A1 true PE20160124A1 (es) 2016-02-24

Family

ID=42238704

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016000013A PE20160124A1 (es) 2009-05-07 2010-05-04 Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr
PE2011001877A PE20120812A1 (es) 2009-05-07 2010-05-04 Compuestos vinil indazolilo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001877A PE20120812A1 (es) 2009-05-07 2010-05-04 Compuestos vinil indazolilo

Country Status (34)

Country Link
US (1) US8268869B2 (es)
EP (1) EP2427449B1 (es)
JP (1) JP5555314B2 (es)
KR (1) KR101373910B1 (es)
CN (1) CN102421769B (es)
AR (1) AR078411A1 (es)
AU (1) AU2010246114B2 (es)
BR (1) BRPI1013748A2 (es)
CA (1) CA2760535C (es)
CL (1) CL2011002781A1 (es)
CO (1) CO6450624A2 (es)
CR (1) CR20110580A (es)
DK (1) DK2427449T3 (es)
EA (1) EA018149B1 (es)
EC (1) ECSP11011441A (es)
ES (1) ES2408117T3 (es)
HN (1) HN2011002809A (es)
HR (1) HRP20130323T1 (es)
IL (1) IL216004A (es)
JO (1) JO2860B1 (es)
MA (1) MA33244B1 (es)
ME (1) ME01462B (es)
MX (1) MX2011011342A (es)
MY (1) MY160390A (es)
NZ (1) NZ595553A (es)
PE (2) PE20160124A1 (es)
PL (1) PL2427449T3 (es)
PT (1) PT2427449E (es)
RS (1) RS52795B (es)
SG (1) SG175909A1 (es)
SI (1) SI2427449T1 (es)
TW (1) TWI382982B (es)
UA (1) UA104756C2 (es)
WO (1) WO2010129509A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
HK1205528A1 (en) 2012-03-08 2015-12-18 Astellas Pharma Inc. Novel fgfr3 fusion product
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AU2014236947A1 (en) 2013-03-15 2015-09-03 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
JP6898306B2 (ja) * 2015-08-07 2021-07-07 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
US10214515B2 (en) 2015-08-20 2019-02-26 Zhejiang Hisun Pharmaceutical Co., Ltd. Substituted pyrazoles as inhibitors of fibroblast growth factor receptor
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021088859A1 (zh) * 2019-11-06 2021-05-14 暨南大学 吲唑类化合物及其药用组合物和应用
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022033472A1 (zh) * 2020-08-11 2022-02-17 河南迈英诺医药科技有限公司 Fgfr抑制剂化合物及其用途
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN116554148B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种乙烯基吲唑类氘代fgfr抑制剂药物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
ATE386736T1 (de) 2000-09-11 2008-03-15 Novartis Vaccines & Diagnostic Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
KR20050004214A (ko) * 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
BRPI0511533A (pt) 2004-05-26 2008-01-02 Pfizer derivados indazol e indolona e seu uso como medicamento
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
CN101594862B (zh) 2006-12-20 2015-11-25 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代吲唑衍生物
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
NZ581698A (en) 2007-06-05 2012-09-28 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
EP2265270A1 (en) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors

Also Published As

Publication number Publication date
CA2760535C (en) 2014-01-14
TWI382982B (zh) 2013-01-21
AR078411A1 (es) 2011-11-09
HK1163665A1 (en) 2012-09-14
PE20120812A1 (es) 2012-07-08
BRPI1013748A2 (pt) 2016-04-05
JP2012526126A (ja) 2012-10-25
MY160390A (en) 2017-03-15
IL216004A0 (en) 2012-01-31
AU2010246114A1 (en) 2011-11-03
CR20110580A (es) 2012-01-06
KR101373910B1 (ko) 2014-03-12
ES2408117T3 (es) 2013-06-18
AU2010246114B2 (en) 2012-12-06
CN102421769B (zh) 2014-04-02
MX2011011342A (es) 2011-11-18
TW201105652A (en) 2011-02-16
MA33244B1 (fr) 2012-05-02
JP5555314B2 (ja) 2014-07-23
SI2427449T1 (sl) 2013-05-31
CL2011002781A1 (es) 2012-05-25
CO6450624A2 (es) 2012-05-31
PT2427449E (pt) 2013-05-06
ME01462B (me) 2014-04-20
NZ595553A (en) 2013-05-31
KR20120004511A (ko) 2012-01-12
CA2760535A1 (en) 2010-11-11
US20100286209A1 (en) 2010-11-11
HRP20130323T1 (en) 2013-05-31
SG175909A1 (en) 2011-12-29
RS52795B (sr) 2013-10-31
EA201171367A1 (ru) 2012-04-30
CN102421769A (zh) 2012-04-18
EA018149B1 (ru) 2013-05-30
EP2427449A1 (en) 2012-03-14
JO2860B1 (en) 2015-03-15
WO2010129509A1 (en) 2010-11-11
EP2427449B1 (en) 2013-04-03
IL216004A (en) 2014-01-30
ECSP11011441A (es) 2011-12-30
UA104756C2 (uk) 2014-03-11
DK2427449T3 (da) 2013-04-22
PL2427449T3 (pl) 2013-08-30
HN2011002809A (es) 2013-07-22
US8268869B2 (en) 2012-09-18

Similar Documents

Publication Publication Date Title
PE20160124A1 (es) Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr
JO3062B1 (ar) R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
MX373178B (es) Fungicidas de benceno sustituido.
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
ZA201100026B (en) 4-(pyridin-4-yl)-1h-(1,3,5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
NZ594163A (en) Pyranose derivatives of pestcidal 1,2,4-triazoles
UY31811A (es) Azoles sustituidos como fungicidas
PE20190343A1 (es) Combinaciones de compuestos activos
CL2009000923A1 (es) Compuestos derivados de 1-(aminoacetil)-n-(1-cicloalquil)pirrolidina-2-carboxamida sustituidas; composicion farmaceutica; utiles para tratar la hepatitis c.
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
MX346186B (es) Inhibidores de proteina cinasas.
CU24020B1 (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
ECSP088781A (es) Derivados de benzimidazol
AR087700A1 (es) Inhibidores de aldh-2 en el tratamiento de adicciones
TH132151A (th) ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก
CY1117146T1 (el) Κρυσταλλικη (r)-(ε)-2-(4-(2-(5-(1-(3,5-διχλωροπυριδινο-4-υλ)αιθοξυ)-1 η-ινδαζολο-3-υλ)βινυλο)-1 η-πυραζολο-1-υλ)αιθανολη και η χρηση της ως αναστολεα του fgfr
ECSP099383A (es) Derivado piperidínico utilizado para tratar enfermedades mediadas por el receptor 5 de quimiocina
TH115254A (th) สารประกอบไวนิลอินดาโซลอิล
IN2013MU02719A (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed